Radioembolization Versus Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study

Keyphrases

• Adverse Events 66%
• Chemoembolization 100%
• Comparative Analysis 33%
• Comparative Effectiveness 33%
• Comparative Toxicity 33%
• Disease Control Rate 33%
• Doxorubicin 33%
• Drug-eluting Beads 33%
• Hepatocellular Cancer 33%
• Hepatocellular Carcinoma 33%
• Locoregional Therapy 100%
• Overall Survival 100%
• Progression-free Survival 66%
• Propensity Matching 33%
• Propensity Score Matching 66%
• Propensity Score Matching Study 100%
• Radioembolization 100%
• Resectable Disease 33%
• Treatment Selection Bias 33%
• Tumor Response 33%
• Unresectable HCC 33%
• Unresectable Hepatocellular Carcinoma 100%

Medicine and Dentistry

• Adverse Event 66%
• Diseases 66%
• Doxorubicin 33%
• Hepatocellular Carcinoma 100%
• Malignant Neoplasm 33%
• Neoplasm 33%
• Overall Survival 100%
• Progression Free Survival 66%
• Propensity Score Matching 66%
• Radioembolization 100%
• Selection Bias 33%
• Transcatheter Arterial Chemoembolization 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 66%
• Diseases 66%
• Doxorubicin 33%
• Liver Cell Carcinoma 100%
• Malignant Neoplasm 33%
• Neoplasm 33%
• Overall Survival 100%
• Progression Free Survival 66%